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Objective: The purposes of this study are to evaluate the outcome of extracorporeal
membrane oxygenation support in a subgroup of patients with Hantavirus cardiopul-
monary syndrome who had a predicted mortality of 100% and to assess the compli-
cations associated with this treatment modality and with different cannulation
techniques.
Methods: Thirty-eight patients with severe Hantavirus cardiopulmonary syndrome
were supported with extracorporeal membrane oxygenation between April 1994
and June 2006. Cannulation of the femoral vessels was performed on an emergency
basis by a percutaneous approach in 15 (39.5%) and by an open technique in 23
(60.5%) patients. Duration of extracorporeal membrane oxygenation averaged 132
hours (range: 5–276 hours).
Results: Complications from percutaneous cannulation occurred in 4 (26.6%) of 15
patients: retroperitoneal hematoma in 2 (13.3%) and lower extremity ischemia in 2
(13.3%) patients, which resolved after insertion of a distal perfusion cannula. Compli-
cations from open femoral cannulation occurred in 8 (34.8%) of 23 patients: severe
bleeding in 7 (30.4%) patients and lower extremity ischemia in 1 (4.3%) patient
who required a leg amputation. The overall survival was 60.5% (23/38 patients).
Six (40%) of the 15 patients cannulated percutaneously and 9 (39.1%) of 23 patients
who had open cannulation died. All survivors recovered completely and were dis-
charged from the hospital after a mean hospital stay of 20.8 days (range: 10–39 days).
Conclusions: Almost two thirds of the patients with severe Hantavirus cardiopulmo-
nary syndrome who were supported with extracorporeal circulation survived and
recovered completely. The complications associated with both types of femoral
cannulation may be attributed to the fact that all patients were in shock or in full
cardiac arrest, and the procedure had to be done expeditiously. Earlier institution of
extracorporeal membrane oxygenation may decrease the complication rates and
improve the overall survival.
H
antaviral infection was first recognized in the Four Corners region of the
American southwest in 1993, during an outbreak of unexplained deaths in
previously healthy young individuals in whom acute onset of respiratory fail-
ure and pulmonary edema developed.1 This clinical syndrome was initially called
Hantavirus pulmonary syndrome. Since most deaths are caused by myocardial dys-
function and hypoperfusion, several investigators prefer the term Hantavirus cardio-
pulmonary syndrome (HCPS).2 The Sin Nombre virus (SNV) has been identified as
the etiologic agent of HCPS and is carried by the deer mouse Peromyscus manicula-
tus. The SNV is transmitted primarily by inhalation of urine and feces of contaminated
rodents.3 Currently, there are no antiviral drugs, vaccines, or immunotherapeutic
agents available for treatment of the disease, and therapy is primarily supportive.4 De-
spite greater awareness and recognition of HCPS and improvement in critical care
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management, mortality rates from 43% to 76% have been
reported.5,6 In 1998, Crowley and associates7 reported our
initial experience with the use of venoarterial extracorporeal
membrane oxygenation (ECMO) as a rescue therapy in
3 patients with severe cardiopulmonary failure owing to
HCPS. The purpose of the present study is to evaluate the
outcome of ECMO support in a subgroup of patients with
HCPS who had a predicted mortality of 100% and to assess
the complications associated with this treatment modality
and with different cannulation techniques.
Patients and Methods
Patient Selection
We reviewed retrospectively the medical records of 38 consecutive
patients with severe cardiopulmonary failure resulting from hantavi-
ral infection treated with venoarterial ECMO at the University of
New Mexico Health Sciences Center from April 1994 to June
2006. Approval by the institutional review board was obtained,
and informed consent was obtained from each patient or the closest
relative.
The University of New Mexico Health Sciences Center is the re-
ferral center for patients with the presumed diagnosis of Hantavirus
infection. Patients were referred from the Four Corners region (New
Mexico, Arizona, Colorado, and Utah) presenting with a brief his-
tory of fever, headache, and myalgias, followed by rapid deteriora-
tion, characterized by respiratory distress, and diffuse pulmonary
infiltrates on chest radiograph. Most patients had a history of expo-
sure to rodent droppings while cleaning a shed or a building 1 or 2
weeks before experiencing symptoms. Early presumptive diagnosis
of Hantavirus infection was strongly suspected by the presence of
thrombocytopenia, hemoconcentration, myelocytosis, and at least
10% lymphocytes with immunoblastic features in the peripheral
blood smear.8 Serologic tests were positive for SNV antibodies in
100% of the patients. All patients were observed in the intensive
care unit, with a radial artery line and a hemodilution catheter
(Swan-Ganz; Edwards LifeSciences, Irvine, Calif) inserted through
the left subclavian vein (to have the right side of the neck available
for possible cannulation of the right internal jugular vein). Arterial
blood gases, serum lactate levels, and cardiac index were recorded
frequently. Several patients needed supportive treatment only and
were not included in this study.
Most patients with HCPS went into shock precipitously, and the
cardiac index was unobtainable at the time of cannulation. Selection
criteria for ECMO support are summarized in Table 1. The current
inclusion criteria for starting patients on ECMO are as follows:
a clinical presentation consistent with HCPS, a cardiac index that580 The Journal of Thoracic and Cardiovascular Surgery c Marrapidly drops to less than 2.0 L $ min21 $ m22, an arterial oxygen
tension/inspired oxygen fraction (PaO2/FIO2) ratio of less than 60,
or cardiopulmonary deterioration with refractory shock despite
maximum inotropic support. Only 1 patient, who was 75 years old
and was in multiorgan system failure and neurologically compro-
mised before transfer, was not considered for ECMO support.
Thirty-eight patients who did not respond to maximal conven-
tional medical therapy were cannulated and placed on ECMO on
an emergency basis. They are the basis of this report. They represent
approximately 75% of the patients treated for HCPS at our institu-
tion. Their ages ranged from 11 to 69 years (mean age: 41.9 years)
(Figure 1). There were 21 (55%) female and 17 (45%) male patients.
On admission to the hospital, 13 (34.2%) patients were in hemody-
namically stable condition but required increasing oxygen concen-
trations. The other 25 (65.8%) patients were intubated before
transfer to our hospital. Before cannulation, 38 (100%) patients
were receiving inotropic agents because of hemodynamic deteriora-
tion, and 8 (21%) required external cardiac compressions.
Pre-ECMO mean arterial pressure ranged from 0 to 87 mm Hg
(mean: 52 mm Hg); PO2 ranged from 28 to 154 mm Hg (mean
PO2: 65 mm Hg); pH ranged from 6.89 to 7.49 (mean pH: 7.31);
serum lactate level ranged from 1.1 to 20.9 mmol/L (mean lactate
level: 7.3 mmol/L); and platelet count ranged from 12,000 to
63,000 (mean platelet count: 32,000).
Patients were cannulated for ECMO when their clinical condi-
tion deteriorated, as indicated previously. Thirteen (34.2%) patients
who were not intubated before arrival were intubated at the same
TABLE 1. Criteria for starting ECMO (In addition to clinical
presentation consistent with HCPS and a cardiac index
less than 2.0 L $ min21 $ m22)
Refractory shock 38 (100 %)
Severe hypoxia (PaO2/FIO2 ratio , 60) 23 (60.5 %)
External cardiac massage 8 (21.0 %)
ECMO, Extracorporeal membrane oxygenation;HCPS,Hantavirus cardiopul-
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Figure 1. Age distribution of patients with Hantavirus infection
supported with ECMO.ch 2008
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Ptime that preparations were being made for cannulation for ECMO.
In some patients we did not wait for a positive serology test, which
takes 8 to 12 hours.
Cannulation and Decannulation Technique
An attempt was made to insert the cannulas percutaneously into the
femoral vessels whenever possible. In patients who were in
hemodynamically stable condition and not yet intubated, a 16-
gauge/7-inch long catheter (Arrow arterial/venous catheterization
set; Arrow International, Inc, Reading, Pa) was inserted percutane-
ously into the common femoral artery and another into the common
femoral vein, using local anesthesia and the Seldinger technique.
Once the decision was made to cannulate for ECMO, the patient
received an initial dose of heparin, 200 units/kg. Subsequently,
a 0.038-inch/39-inch long guidewire, included with the Bio-
Medicus percutaneous arterial femoral kit (Medtronic Inc, Minneap-
olis, Minn), was introduced into the previously placed catheter in the
femoral artery. A Bio-Medicus femoral arterial cannula, ranging in
size from 15F to 21F/18-cm long, was inserted over the guidewire
and then connected to the arterial tubing from the ECMO machine.
Likewise, a 0.038-inch/71-inch long guidewire, provided with the
Bio-Medicus percutaneous femoral kit, was introduced into the
previously placed catheter in the femoral vein. A Bio-Medicus fem-
oral venous cannula, ranging in size from 22F to 29F/76-cm long,
was placed over the guidewire and advanced to the right atrium. It
was then connected to the venous tubing of the ECMO machine.
Eight patients with pulseless electrical activity and/or ventricular
fibrillation were cannulated by the open technique during external
cardiac compressions.
To prevent ischemia of the lower extremity, we used a size 8F or
10F/10-cm long Bio-Medicus pediatric arterial cannula with obtura-
tor for distal perfusion of the superficial femoral artery in 20 of the
23 patients cannulated with the open approach. In addition, a distal
venous cannula, size 14F to 20F, was inserted distally into the
femoral vein in 5 patients to relieve venous congestion.
Five (13%) patients had poor venous drainage because the
venous cannula could not be advanced into the inferior vena cava
by the femoral approach. In these patients, a Thin-Flex single-stage
venous cannula (Edwards Lifesciences LLC, Irvine, Calif), ranging
in size from 30F to 36F, was advanced without difficulty into the
right atrium through the right internal jugular vein, which was
exposed via an oblique neck incision anterior to the sternocleido-
mastoid muscle.
Patients were connected to the ECMO machine (Cobe Cardio-
vascular, Arvada, Colo) with a Wolf custom-pack nonheparinized
3/8-inch tubing (Medtronic Inc, Minneapolis, Minn), with an
Avecor membrane oxygenator (Medtronic) and a Bio-Therm heat
exchanger (Medtronic). The initial ECMO pump settings included
a flow of 4.0 to 5.0 L/min delivered by a roller pump system and
an FIO2 of 1.0. Anticoagulation was maintained with heparin, and
the activated clotting time (ACT) was monitored hourly, with values
ranging from 180 to 220 seconds. After a few days of ECMO, the
inotropic agents and FIO2 were weaned, as the hemodynamic status
and pulmonary function improved gradually. Subsequently, the
patients were weaned from ECMO, and when the pump flow was
less than 1 L/min and 1-hour trials off ECMO were tolerated,
ECMO support was discontinued. The ACT was maintained greater
than 200 seconds during the trials off ECMO to prevent clotting of
the cannulas. Clotting of the femoral artery or vein was not an issue,The Journal of Thorbecause the patients were kept fully anticoagulated until the cannu-
las were removed. The cannulas were removed by an open
approach. An additional 5000 units of heparin were given intrave-
nously if the ACT was less than 200 seconds. After removal of
the arterial cannula, a Fogarty embolectomy catheter was passed dis-
tally to retrieve any possible clots. The common femoral artery was
repaired primarily in 14 patients by continuous 6–0 polypropylene
suture or by a patch of autologous saphenous vein in 11 patients.
Likewise, the common femoral vein was repaired primarily with
continuous 6–0 polypropylene suture or with a patch of autologous
saphenous vein in 2 patients. Normal distal pulses were present after
decannulation in all patients who survived ECMO.
Statistical Analysis
The Fisher exact test was used to compare several categorical vari-
ables associated with increased mortality during ECMO support
(Table 2), and the unpaired Student t test was used for comparison
of continuous variables (Table 3).
Results
Duration of ECMO support averaged 132 hours (range: 67–
276 hours in survivors and 5–262 hours in nonsurvivors). Af-
ter ECMO was discontinued, all patients remained intubated
for an average of 7.1 days (range: 3–12 days), and 3 patients
required a tracheostomy.
The hospital mortality was 39.5% (15 patients), of whom
13 patients died during ECMO support and 2 additional
patients died of multiorgan system failure after ECMO was
discontinued by family request. The overall survival was
60.5% (23/38 patients). There was no significant difference
in mortality for patients supported with ECMO for more
than 7 days (5/11 died, mortality 5 45.4%) when compared
with patients supported with ECMO for less than 7 days (10/
27 died, mortality 5 37%) (P 5 .753). Six (75%) of the
8 patients who had cardiac arrest before cannulation died of
hypoxic–ischemic encephalopathy, 3 of whom also had mul-
tiorgan system failure. Other causes of death included multi-
organ system failure in another 5 patients and sepsis and renal
failure in 4 patients. Our results indicate that pre-ECMO car-
diac arrest, severe lactic acidosis, and severe hypotension
TABLE 2. Categorical variables associated with increased
mortality during ECMO support, compared by the Fisher
exact test
Variable Survivors Nonsurvivors P value
Female gender 12/21 (57.1%) 9/21 (42.9%) .789
Male gender 11/17 (64.7%) 6/17 (35.3%) .744
Intubated before
transfer
16/23 (69.6%) 9/15 (60%) .728
Pre-ECMO CPR 2/23 (8.7%) 6/15 (40%) .039
1994–1999 8/16 (50%) 8/16 (50%) .426
2000–2006 7/22 (68.2%) 7/22 (31.8%) .426
CPR, Cardiopulmonary resuscitation; ECMO, extracorporeal membrane
oxygenation. Boldface indicates statistically significance.acic and Cardiovascular Surgery c Volume 135, Number 3 581
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Student t test.
Variable Survivors Nonsurvivors P value
Age 11 2 62 (x 5 40.1) 15 2 69 (x 5 44.7) .329
Weight 50 2 103 kg (x 5 75 kg) 55 2 107 kg (x 5 81.8 kg) .177
Pre-ECMO platelet count 13,000 2 63,000 (x 5 35,700) 12,000 2 43,000 (x 5 25,500) .073
Pre-ECMO MAP 36 2 80 (x 5 60.9 mm Hg) 0 2 74 (x 5 40.8 mm Hg) .038
Pre-ECMO pH 6.9 2 7.48 (x 5 7.30) 7.05 2 7.49 (x 5 7.32) .893
Pre-ECMO serum lactate 2.0 2 18.2 (x 5 4.7 mmol/L) 2.5 2 23.0 (x 5 11.4 mmol/L) .002
Pre-ECMO PaO2 28 2 195 (x 5 81) 32 2 154 (x 5 65) .301
Hours on ECMO 67 2 276 (x 5 135.2) 5 2 262 (x 5 127.7) .753
ECMO, Extracorporeal membrane oxygenation; MAP, mean arterial pressure. Boldface indicates statistically significant.were associated with significantly increased mortality (P ,
.05) (Tables 2 and 3).
All patients who were successfully weaned and decannu-
lated survived and recovered completely and were dis-
charged from the hospital after a mean hospital stay of 20.8
days (range: 10–39 days). We observed that survival
improved during the last few years. Before January 2000, 8
(50%) of 16 patients died, whereas 7 (31.8%) of 22 patients
died since January 2000. However, there was no significant
statistical difference between the two time periods (P 5
.426). Sixteen of the 23 survivors had an uneventful course
on ECMO and no complications.
No difference in survival was observed when percutane-
ous and open techniques of cannulation were compared.
Six (40%) of the 15 patients cannulated percutaneously and
9 (39.1%) of the 23 patients who had open cannulation
died. Complications from percutaneous cannulation occurred
in 4 (26.6%) of 15 patients. Two (13.3%) of 15 patients had
a large retroperitoneal hematoma develop, and 2 (13.3%) of
15 patients had lower extremity ischemia develop. Adequate
leg perfusion was re-established with thrombectomy–embo-
lectomy and after insertion of an additional cannula in the
superficial femoral artery.
Complications from open femoral cannulation occurred in
8 (34.8%) of 23 patients: severe bleeding occurred in 7
(30.4%) of 23 patients, and 1 (4.3%) patient required a leg
amputation because of lower extremity ischemia despite
insertion of a distal perfusion cannula. Six (50%) of the 12
patients with cannulation complications did not survive: 3
(100%) of 3 patients with leg ischemia and 3 (42.8%) of
7 patients with severe bleeding died. In contrast, 9 (34.6%)
of the 26 patients without cannulation complications did
not survive. However, the difference in mortality between
the patients who had serious cannulation complications and
those who did not was not statistically significant (P 5 .80).
Severe bleeding necessitating re-exploration occurred in 7
(30.4%) of 23 patients after open femoral cannulation, and
the median number of transfused units of red blood cells
and platelets was 21.4 (range: 6–65 units) and 18 (range:
2–83), respectively. Bleeding originated around the venous582 The Journal of Thoracic and Cardiovascular Surgery c Mcannula in 2 patients, at the arterial cannulation site in
2 patients, was due to partial dislodgment of the superficial
femoral artery cannula in 2 patients, and was caused by nee-
dle holes in another patient. Three (42.8%) of the 7 patients
with severe bleeding from the cannulation site died, but there
was no statistically significant difference in mortality when
compared with 9 (34.6%) of 26 patients without cannulation
complications who did not survive (P 5 .80).
Other serious complications that we observed during
ECMO support included mechanical problems in 3 patients
who did not survive (tubing rupture in 2 and pump malfunc-
tion in 1) and patient complications (sepsis and renal failure
in 6 patients, 2 of whom survived, and multiorgan system
failure in 8 patients, who did not survive).
Discussion
HCPS resulting from SNV infection is characterized by 4
clinical phases: prodrome, pulmonary edema and shock,
diuretic phase, and convalescence.6 Clinical presentation
during the prodromal phase is characterized by high fever,
headache, and myalgias for an average of 3 to 6 days, fol-
lowed by dyspnea, which is frequently a sign of impending
respiratory failure. The onset of respiratory distress and
shock is abrupt. Risk of death is highest during the initial
24 hours of the pulmonary edema and shock phase of the
illness, which also lasts from 3 to 6 days.
Despite early diagnosis of HCPS, improvement in critical
care management, including mechanical ventilation, and he-
modynamic support with vasoactive drugs, mortality rates
range from 43% to 76%.5,6 Some patients, however, have
a worse prognosis than others and are unlikely to survive
despite aggressive medical management. Crowley and
colleagues7 identified several criteria for nonsurvival, which
include refractory shock, severe hypoxia (PaO2/FIO2 ratio ,
60), and external cardiac compressions. In our present study,
only those patients with a typical clinical presentation consis-
tent with HCPS, a cardiac index that rapidly dropped to less
than 2.0 L $ min21 $ m22 despite maximum inotropic sup-
port, and at least one of the predictive criteria for nonsurvival
mentioned above were considered for ECMO support. Earlyarch 2008
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Pdiagnosis of Hantavirus infection is strongly suspected by
characteristic hematologic findings, including thrombocyto-
penia, hemoconcentration, leukocytosis, and the presence
of at least 10% immunoblasts in the peripheral blood smear.8
The diagnosis of HCPS is confirmed by the presence of SNV
antibodies. However, a major limitation of the serologic test
is that it usually takes 8 to 12 hours, whereas a recombinant
immunoblot assay allows the diagnosis within 4 hours.6 In
contrast to patients with other forms of septic shock, patients
with HCPS have a decreased cardiac index and elevated sys-
temic vascular resistance.9 Although the usual chest radio-
graphic findings include interstitial edema early in the
disease course and lack of peripheral distribution of air space
disease,10 the hemodynamic parameters in HCPS are unique
because the pulmonary artery wedge pressure is low, unlike
other forms of cardiogenic shock, and these patients fail to
improve with intravascular volume repletion, unlike other
forms of hypovolemic shock.6
Treatment of HCPS during the pulmonary edema and
shock phase poses a dilemma, because severe pulmonary
capillary leak develops during volume administration.
Inotropic support with dobutamine and mechanical ventila-
tion are indicated during this phase to improve cardiac output
and oxygenation. However, some patients fail to improve,
and lactic acidosis and pulseless electrical activity develop
rapidly.
Venoarterial cannulation for ECMO was used to treat our
patients with HCPS because it provides support for both
cardiac and respiratory failure. Venovenous ECMO is an al-
ternative method of extracorporeal support for patients with
severe respiratory failure who do not require cardiac support,
but it is not applicable to treat patients with HCPS. A roller
pump was used for all patients supported with ECMO,
mainly because it provides a constant flow and is associated
with a reduced risk of hemolysis.11
Vascular access can be accomplished percutaneously or
by direct cutdown of the common femoral artery and vein.
As an initial step before cannulation, we prefer to introduce
percutaneously a guidewire and a sheath in the common fem-
oral artery and another in the common femoral vein in
patients who are in hemodynamically stable condition. This
simple maneuver facilitates percutaneous insertion of the
cannulas into the femoral vessels once the decision is made
to cannulate for ECMO. However, cannulation of the femoral
vessels was achieved percutaneously in only 15 (39.5%)
patients, and an open technique was required in the other
23 (60.5%) patients. Cannulation during cardiac massage
(8 patients) and difficulty inserting the cannula percutane-
ously into the femoral vein were the most common reasons
requiring open cannulation. Axillary cannulation was not
considered because it is more time consuming and may
lead to more bleeding complications.
Poor venous drainage was usually corrected by reposition-
ing the tip of the venous cannula in the right atrium.The Journal of ThorAdditional cannulation of the right internal jugular vein
was required in 5 (13.1%) patients because the venous
cannula could not be advanced into the inferior vena cava
by the femoral approach. Insertion of an additional venous
cannula in the distal femoral vein, as described by Le
Guyader and colleagues,12 was required in 5 patients to
relieve venous leg congestion.
Ischemic injury of the lower extremity is a potential com-
plication associated with prolonged ECMO support. In our
experience, leg ischemia occurred in 3 (7.9%) patients, of
whom 2 were cannulated percutaneously. To prevent this
serious complication, we used to insert a distal perfusion can-
nula in the superficial femoral artery in all patients cannulated
with the open technique, as recommended by several au-
thors.13,14 More recently, we have used a distal perfusion
cannula in the posterior tibial artery inserted under direct
vision in all patients. Huang and colleagues15 use a pressure
criterion to select the patients at risk of distal leg ischemia and
place a perfusion catheter if the distal mean pressure is below
50 mm Hg. An alternative method of femoral arterial cannu-
lation using a single right-angle cannula, which maintains ad-
equate bidirectional arterial perfusion, was described by
Read and associates.16
Bleeding is the most common complication of ECMO,
mainly because of systemic heparinization.17 Thrombocyto-
penia and platelet dysfunction are incremental risk factors
for surgical bleeding in patients with Hantavirus infection.
Severe hemorrhage may lead to profound hemodynamic
decompensation during ECMO. Management of bleeding in-
cludes volume-for-volume replacement of blood loss, plate-
let transfusion to more than 125,000/mm3, and decreasing
the ACT to 180 seconds. Epsilon aminocaproic acid, aproti-
nin, and tranexamic acid have recently been reported to min-
imize bleeding complications in patients supported by
ECMO.17 Despite aggressive treatment of the underlying
coagulopathy, surgical re-exploration of the cannulation
site is usually necessary. According to the Registry Report
2004 of the Extracorporeal Life Support Organization, can-
nulation site bleeding occurred in 22% and 29% of adult pa-
tients supported by ECMO for respiratory failure and cardiac
support, respectively.18 Magovern and Simpson19 reported
that bleeding was noted in most patients with postcardiotomy
cardiogenic shock supported by ECMO, 48% required reop-
eration for femoral vessel repair, and the average number of
units of red blood cells and platelets transfused was 29 and
36, respectively. In our series, severe bleeding necessitating
re-exploration occurred in 30% of patients after open femoral
cannulation, a large retroperitoneal hematoma developed
after percutaneous cannulation in 13% of patients, and the
average number of units of red blood cells and platelets
transfused was 21 and 18, respectively. Although the bleed-
ing complications might have been easier to manage with
a centrifugal pump and heparin-coated circuits, the tradeoff
is that centrifugal pumps do not have servo-regulation, whichacic and Cardiovascular Surgery c Volume 135, Number 3 583
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with a significantly increased risk of hemolysis.11
The overall survival in our series was 60.5% (23/38
patients). By comparison, survival of adults supported by
ECMO for postcardiotomy cardiogenic shock was 36% in
the Allegheny experience19; it was 40% for adult cardiac fail-
ure and 54% for adult respiratory failure as reported in the
2004 Extracorporeal Life Support Organization Registry.18
In conclusion, almost two thirds of the patients with severe
HCPS who were supported with ECMO survived and recov-
ered completely. The complications associated with both
types of femoral cannulation may be attributed to the fact
that all patients were in shock or in full cardiac arrest, and
the procedure had to be done expeditiously. Earlier institu-
tion of ECMO and refinement of cannulation techniques
may decrease the complication rates and improve the overall
survival.
We are very grateful to Cameron Crandall, MD, PhD (Research
Director, Department of Emergency Medicine, University of New
Mexico Health Sciences Center), for the statistical analysis; to
Patrick Kelly, John Clement, and Will Cabaniss (Perfusion Services
at University of New Mexico Health Sciences Center); to Denise
Coleman, MD, and Robert Katz, MD (Department of Pediatrics,
University of New Mexico Health Sciences Center); and to Gary
Iwamoto, MD, Michel Boivin, and Michele Harkins, MD (Division
of Critical Care Medicine, Department of Internal Medicine, Uni-
versity of New Mexico Health Sciences Center).
References
1. Nichol ST, Spiropoulou CF, Morzunov S, Rollin PE, Ksiazek TG,
Feldmann H, et al. Genetic identification of a hantavirus associated
with an outbreak of acute respiratory illness. Science. 1993;262:914-7.
2. Ye C, Prescott J, Nofchissey R, Goade D, Hjelle B. Neutralizing
antibodies and Sin Nombre virus RNA after recovery from hantavirus
cardiopulmonary syndrome. Emerg Infect Dis. 2004;10:478-82.
3. Childs JE, Ksiazek TG, Spiropoulou CF, Krebs JW, Morzunov S,
Maupin GO, et al. Serologic and genetic identification of Peromyscus
maniculatus as the primary rodent reservoir for a new hantavirus in
the southwestern United States. J Infect Dis. 1994;169:1271-80.584 The Journal of Thoracic and Cardiovascular Surgery c Ma4. Ferre´s M, Vial P. Hantavirus infection in children. Curr Opin Pediatr.
2004;16:70-5.
5. Young JC, Hansen GR, Graves TK, Deasy MP, Humphreys JG,
Fritz CL, et al. The incubation period of Hantavirus pulmonary
syndrome. Am J Trop Med Hyg. 2000;62:714-7.
6. Simpson SQ. Hantavirus pulmonary syndrome. Heart Lung. 1998;27:
51-7.
7. Crowley MR, Katz RW, Kessler R, Simpson SQ, Levy H, Hallin G, et al.
Successful treatment of adults with severe Hantavirus pulmonary
syndrome with extracorporeal membrane oxygenation. Crit Care Med.
1998;26:409-14.
8. Koster F, Foucar K, Hjelle B, Scott A, Chong YY, Larson R, et al. Rapid
presumptive diagnosis of Hantavirus cardiopulmonary syndrome by
peripheral blood smear review. Am J Clin Pathol. 2001;116:665-72.
9. Hallin GW, Simpson SQ, Crowell RE, James DS, Koster FT, Mertz GJ,
et al. Cardiopulmonary manifestations of hantavirus pulmonary
syndrome. Crit Care Med. 1996;24:252-8.
10. Ketai LH, Williamson MR, Telepak RJ, Levy H, Koster FT, Nolte KB,
et al. Hantavirus pulmonary syndrome: radiographic findings in
16 patients. Radiology. 1994;191:665-8.
11. Hansell DR. ECLS equipment and devices. In: Van Meurs K, Lally KP,
Peek G, Zwischenberger JB, editors. Extracorporeal cardiopulmonary
support in critical care. 3rd ed. Ann Arbor: Extracorporeal Life Support
Organization; 2005. p. 107-19.
12. Le Guyader A, Lacroix P, Ferrat P, Laskar M. Venous leg congestion
treated with distal venous drainage during peripheral extracorporeal
membrane oxygenation. Artif Organs. 2006;30:633-5.
13. Greason KL, Hemp JR, Maxwell JM, Fetter JE, Moreno-Cabral RJ.
Prevention of distal limb ischemia during cardiopulmonary support
via femoral cannulation. Ann Thorac Surg. 1995;60:209-10.
14. Ceviz M, Ozyazicioglu A, Koc¸ak H. The prevention of leg ischemia in
femoral cannulation. Ann Thorac Surg. 1999;67:1217.
15. Huang SC, Yu HY, Ko WJ, Chen YS. Pressure criterion for placement of
distal perfusion catheter to prevent limb ischemia during adult extracor-
poreal life support. J Thorac Cardiovasc Surg. 2004;128:776-7.
16. Read R, St Cyr J, Tornabene S, Whitman G. Improved cannulation
method for extracorporeal membrane oxygenation. Ann Thorac Surg.
1990;50:670-1.
17. DeBerry BB, Lynch J, Chung DH, Zwischenberger JB. Emergencies
during ECLS and their management. In: Van Meurs K, Lally KP,
Peek G, Zwischenberger JB, editors. Extracorporeal cardiopulmonary
support in critical care. 3rd ed. Ann Arbor: Extracorporeal Life Support
Organization; 2005. p. 133-56.
18. Conrad SA, Rycus PT, Dalton HJ. Extracorporeal Life Support Registry
Report 2004. ASAIO J. 2005;51:4-10.
19. Magovern GJ, Simpson KA. Extracorporeal membrane oxygenation for
adult cardiac support: the Allegheny experience. Ann Thorac Surg.
1999;68:655-61.rch 2008
